Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | NOS1 | P29475 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29680531 | 0.87 | NOS1 (0.54) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL1026662 | 0.87 | NOS1 (0.54) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL31717179 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL3769121 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL2571492 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL16741277 | 0.86 | CHEK1 (0.59) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL616791 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL1024276 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL15534879 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL29680257 | 0.86 | NOS1 (0.53) | MAPTNOS1CYP3A4LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-117203198-A | Compounds as PU.1 inhibitors | 浙江星浩澎博医药有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4247805-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmceuticals (CN) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022105825-A1 | COMPOUNDS AS PU. 1 INHIBITORS | PEKING UNIVERSITY (CN) | 2022-05-27 | — | — | WO | disclosed |
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | Xuanzhu Pharma Co., Ltd. (CN) | 2013-01-24 | — | — | US | disclosed |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | Xuanzhu Pharma Co., Ltd. (CN) | 2013-01-24 | — | — | US | disclosed |
| EP-2532665-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532665-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| CN-102712649-A | Benzimidazole derivatives and pharmaceutical compositions and uses thereof | KBP BIOSCIENCES CO LTD | 2012-10-03 | — | — | CN | disclosed |
| WO-2011095057-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-08-11 | — | — | WO | disclosed |
| US-4013404-A | Method of dyeing hair with indolines, indoles and indazoles | AMERICAN CYANAMID COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | F12, HRH2, H1-3 | MAPT 4289/4885NOS1 1130/4885CYP3A4 47/4885 |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | FLI1, MCL1, SP1 | MAPT 4351/4885NOS1 567/4885CYP3A4 3969/4885 |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | F12, HRH2, H1-3 | MAPT 4289/4885NOS1 1130/4885CYP3A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.